Atea Pharmaceuticals, Inc.
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Atea Pharmaceuticals, Inc.'s yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Debt Due Cover Ratio: Operating cash was negative last year, while some debt falls due within a year. Lower than 89% of Healthcare companies in United States.
- Cash Cushion Ratio: Cash, after subtracting all debt, equals 93% of its market value (net cash). Higher than 87% of Healthcare companies in United States.
- Steadiness Ratio: Sales grew in 0 of the last 3 years; profit grew in 1 of 3. Less steady than 86% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 1/3Sales grew in 0 of the last 3 years; profit grew in 1 of 3.
Less steady than 86% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
-156.6×Operating cash was negative last year, while some debt falls due within a year.
Lower than 89% of Healthcare companies in United States.
Cash Cushion Ratio
+93%Cash, after subtracting all debt, equals 93% of its market value (net cash).
Higher than 87% of Healthcare companies in United States.
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (10)
Atea Pharmaceuticals, Inc. made a loss over the last year. Atea Pharmaceuticals, Inc. owes $0.12 for every $1 it owns. Atea Pharmaceuticals, Inc. made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossAtea Pharmaceuticals, Inc. made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
1.59The share price is 1.59 times Atea Pharmaceuticals, Inc.'s book value per share, lower than 65% of Healthcare companies in United States.
Market cap
$324 MThe total market value of all of Atea Pharmaceuticals, Inc.'s shares at today's price (share price × number of shares), smaller than 51% of Healthcare companies in United States. PosiCap size class: Mini Cap.
Net worth (book value)
$204 MWhat Atea Pharmaceuticals, Inc. would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$2.55Net worth divided by the number of shares. The share price of $4.04 is 1.6 times this, which is the P/B above.
Return on equity (ROE)
-58.1%Atea Pharmaceuticals, Inc. lost 58.1% of its shareholders' money over the last year, lower than 56% of Healthcare companies in United States.
Owes vs Owns
0.12×Atea Pharmaceuticals, Inc. owes $0.12 for every $1 it owns (low), lower than 83% of Healthcare companies in United States.
Dividend yield
NoneAtea Pharmaceuticals, Inc. does not currently pay a dividend.
Profit growth
LossAtea Pharmaceuticals, Inc. made a loss in each of the last two years.
Cash vs debt
Net cashAtea Pharmaceuticals, Inc. held $301 M more cash than debt (net cash) at Dec 2025.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Atea Pharmaceuticals, Inc.: $324 M ÷ $204 M (30 Jun 2026) = 1.6.
What is Atea Pharmaceuticals, Inc.'s return on equity?
Atea Pharmaceuticals, Inc. lost 58.1% of its shareholders' money over the last year, lower than 56% of Healthcare companies in United States.
How much does Atea Pharmaceuticals, Inc. owe compared with what it owns?
Atea Pharmaceuticals, Inc. owes $0.12 for every $1 it owns (low), lower than 83% of Healthcare companies in United States.
Does Atea Pharmaceuticals, Inc. pay a dividend?
No. Atea Pharmaceuticals, Inc. does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.